Codeine dysregulates ribosome biogenesis in Escherichia coli with DNA double-strand breaks to chart path to new classes of antibiotics [0.03%]
可待因通过干扰具有DNA双链断裂的埃希氏 coli的核糖体生物合成来揭示新型抗生素的道路
Vincent Amarh,Benaiah Annertey Abbey,Samuel Akwasi Acheampong et al.
Vincent Amarh et al.
Aim: A bacterial genetics-guided approach was utilized for the discovery of new compounds affecting bacterial genome stability. Materials & methods: ...
Eswara Naga Hanuma Kumar Ghali,Vijian Dhevan,Shravan K Narmala et al.
Eswara Naga Hanuma Kumar Ghali et al.
Alone and together: current approaches to targeting glutaminase enzymes as part of anti-cancer therapies [0.03%]
谷氨酰胺酶在抗癌疗法中的作用及靶向方法研究进展
Thuy-Tien T Nguyen,William P Katt,Richard A Cerione
Thuy-Tien T Nguyen
Metabolic reprogramming is a major hallmark of malignant transformation in cancer, and part of the so-called Warburg effect, in which the upregulation of glutamine catabolism plays a major role. The glutaminase enzymes convert glutamine to ...
Marco Cabrera,Meghana Kolli,Meena Jaggi et al.
Marco Cabrera et al.
CXCR4 as a novel target in immunology: moving away from typical antagonists [0.03%]
CXCR4在免疫学中的新作用靶点：从传统拮抗剂中解脱出来
Birgit Caspar,Pietro Cocchiara,Armelle Melet et al.
Birgit Caspar et al.
CXCR4 has been a target of interest in drug discovery for numerous years. However, so far, most if not all studies focused on finding antagonists of CXCR4 function. Recent studies demonstrate that targeting a minor allosteric pocket of CXCR...
The case for cancer-associated fibroblasts: essential elements in cancer drug discovery? [0.03%]
癌症相关成纤维细胞的案例：癌症药物发现中的关键因素？
Gabrielle Brewer,Anne-Marie Fortier,Morag Park et al.
Gabrielle Brewer et al.
Although cancer-associated fibroblasts (CAFs) have gained increased attention for supporting cancer progression, current CAF-targeted therapeutic options are limited and failing in clinical trials. As the largest component of the tumor micr...
Multitargeted anti-infective drugs: resilience to resistance in the antimicrobial resistance era [0.03%]
针对多重感染目标的抗菌药：对抗微生物抗性时代的耐逆性
Colin J Suckling,Iain S Hunter,Fraser J Scott
Colin J Suckling
The standard drug discovery paradigm of single molecule - single biological target - single biological effect is perhaps particularly unsuitable for anti-infective drug discovery. This is due to the rapid evolution of resistance likely to b...
Withania somnifera as a potential future drug molecule for COVID-19 [0.03%]
Withania somnifera作为未来治疗COVID-19的药物分子潜力探究
Vivek K Kashyap,Anupam Dhasmana,Murali M Yallapu et al.
Vivek K Kashyap et al.
Eric Ni,Eehjoe Kwon,Lauren M Young et al.
Eric Ni et al.
Aim: High-throughput phenotypic screens have emerged as a promising avenue for small-molecule drug discovery. The challenge faced in high-throughput phenotypic screens is target deconvolution once a small molecule hit is ...
Targeting peripheral ϰ-opioid receptors for the non-addictive treatment of pain [0.03%]
靶向外周κ-阿片受体治疗非成瘾性疼痛
Tyler C Beck,Thomas A Dix
Tyler C Beck
Drug addiction to prescription mu-opioid agonists used in the setting of pain is a major public health threat, affecting millions of Americans. Kappa opioid agonists (KOAs) may serve as a possible solution. KOAs have demonstrated indistingu...